Agilent Invests $80M in Lasergen | GenomeWeb

NEW YORK (GenomeWeb) – Agilent Technologies announced Monday that it has invested $80 million in next-generation sequencing technology firm Lasergen, with the ultimate goal of incorporating Lasergen's technology into a clinical sequencing workflow.

Agilent's investment gives it a 48 percent stake in Houston-based Lasergen and a seat on the board of directors. Under the terms of the deal, Agilent also has the option to acquire the smaller company's remaining shares for an additional $105 million. That option expires March 2, 2018.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.

Dec
13
Sponsored by
Agilent Technologies

This webinar will discuss a genomic strategy that detects single nucleotide variants and copy number variants in a single assay.

Dec
15
Sponsored by
PierianDx

This webinar will be an interactive roundtable discussion on established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting.